Article
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Clinical lung cancer - 1 Jul 2009
Nguyen Kim-Son H, Kobayashi Susumu, Costa Daniel B
Abstract excerpt
Most advanced non-small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. However, over time (median of 6-12 months), most tumors develop acquired resistance to EGFR TKIs. Intense research in these NSCLCs has identified two major mechanisms of resistance...
Topics
- Afatinib
- Carcinoma, Non-Small-Cell Lung
- Drug Resistance, Neoplasm
- ErbB Receptors
- Erlotinib Hydrochloride
- Gefitinib
- Gene Amplification
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors